Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors

被引:53
|
作者
Al Koudsi, Nael [2 ]
Hoffmann, Ewa B. [2 ,3 ]
Assadzadeh, Abbas [2 ]
Tyndale, Rachel F. [1 ,3 ]
机构
[1] Univ Toronto, Dept Pharmacol & Toxicol & Psychiat, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada
[3] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada
关键词
CYP2A6; Nicotine; Pharmacogenetics; Age; Gender; HUMAN LIVER-MICROSOMES; C-OXIDATION; POLYMORPHIC ALLELES; CYTOCHROME-P450; EXPRESSION; VARIABILITY; METHYLATION; RECEPTOR; SMOKING;
D O I
10.1007/s00228-009-0762-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We investigated the role of genetic, physiological, environmental, and epigenetic factors in regulating CYP2A6 expression and nicotine metabolism. Human livers (n = 67) were genotyped for CYP2A6 alleles and assessed for nicotine metabolism and CYP2A6 expression (mRNA and protein). In addition, a subset of livers (n = 18), human cryopreserved hepatocytes (n = 2), and HepG2 cells were used for DNA methylation analyses. Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine C-oxidation activity, and affinity for nicotine. Female livers had significantly higher CYP2A6 protein and mRNA expression compared to male livers. Livers exposed to dexamethasone and phenobarbital had higher CYP2A6 expression and activity, however the difference was not statistically significant. Age and DNA methylation status of the CpG island and a regulatory site were not associated with altered CYP2A6. We identified genotype, gender, and exposure to inducers as sources of variation in CYP2A6 expression and activity, but much variation remains to be accounted for.
引用
收藏
页码:239 / 251
页数:13
相关论文
共 50 条
  • [1] Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors
    Nael Al Koudsi
    Ewa B. Hoffmann
    Abbas Assadzadeh
    Rachel F. Tyndale
    European Journal of Clinical Pharmacology, 2010, 66 : 239 - 251
  • [2] Nicotine metabolism:: the impact of CYP2A6 on estimates of additive genetic influence
    Swan, GE
    Benowitz, NL
    Lessov, CN
    Jacob, P
    Tyndale, RF
    Wilhelmsen, K
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (02): : 115 - 125
  • [3] CYP2A6 gene polymorphisms impact to nicotine metabolism
    Muliaty, Dewi
    Yusuf, Irawan
    Setiabudy, Rianto
    Wanandi, Septelia I.
    MEDICAL JOURNAL OF INDONESIA, 2010, 19 (01) : 46 - 51
  • [4] The role of CYP2A6*2 in nicotine metabolism
    Riexinger, A
    Collins, S
    Gaertner, I
    Farger, G
    Batra, A
    NICOTINE & TOBACCO RESEARCH, 2005, 7 (04) : 653 - 653
  • [5] Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6
    Nakajima, M
    Kuroiwa, Y
    Yokoi, T
    DRUG METABOLISM REVIEWS, 2002, 34 (04) : 865 - +
  • [6] Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6
    Yokoi, Tsuyoshi
    DRUG METABOLISM REVIEWS, 2006, 38 : 10 - 11
  • [7] CYP2A6 polymorphism and nicotine metabolism.
    Benowitz, NL
    Tyndale, R
    Jacob, P
    Swan, GE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P41 - P41
  • [8] CYP2A6 polymorphism, nicotine, and environmental nitrosamines
    Idle, JR
    LANCET, 1999, 353 (9169): : 2073 - 2073
  • [9] Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
    Mwenifiumbo, Jill C.
    Tyndale, Rachel F.
    PHARMACOGENOMICS, 2007, 8 (10) : 1385 - 1402
  • [10] Genetic polymorphisms in human Cyp2a6 gene and interindividual differences in nicotine metabolism
    Nakajima, M
    Yoshida, R
    Nishimura, K
    Kwon, JT
    Yokoi, T
    CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM, 2003, : 257 - 260